An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 163
- 试验地点
- 22
- 主要终点
- Duration of febrile episodes (fever)
研究概览
简要总结
The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra supportive care measure after induction chemotherapy for patients with acute myeloid leukemia (AML).
详细描述
The prolonged period of severe neutropenia caused by induction chemotherapy for the treatment of AML is associated with a nearly universal risk of febrile neutropenia. Standard supportive care strategies include administration of prophylactic anti-bacterial and anti-fungal agents, but serious breakthrough bacterial and fungal infections still occur. Granulocyte colony-stimulating factor (G-CSF; filgrastim, Neupogen®) has been shown to shorten the duration of severe neutropenia, fever, antibiotic use and hospitalization following induction chemotherapy for AML. CLT-008, a human allogeneic myeloid progenitor cell product, is intended to provide the cellular target for G-CSF to produce neutrophils during the period of chemotherapy-induced bone marrow suppression when the patient's own progenitor cells may be limited in responding to G-CSF. It is hypothesized that the production of allogeneic neutrophils from CLT-008 will be sufficient to mitigate the infection-related consequences of induction chemotherapy for AML.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute myeloid leukemia arising de novo (per European LeukemiaNet)
- •Treated with any established chemotherapy regimen based on either:
- •7+3: Standard-dose cytarabine 100-200 mg per meter squared continuous infusion for 7 days with idarubicin 12 mg per meter squared or daunorubicin 45-90 mg per meter squared for 3 days
- •High-dose cytarabine-based (HIDAC) chemotherapy administering a total cytarabine dose of ≥ 4 g per meter squared alone or in combination with other anti-leukemic agents (for example, anthracyclines, purine nucleoside inhibitors, etoposide, etc.)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening or by the day chemotherapy is initiated
- •Adequate respiratory function with a room air oxygen saturation of at least 92%
- •Adequate cardiac function defined as an ejection fraction of at least 45%
- •Serum bilirubin ≤ 1.5 times the upper limits of normal. Subjects with a history of Gilbert's syndrome may be enrolled if the total bilirubin is < 3 mg/dL with an indirect bilirubin of > 1.5 mg/dL
- •Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times upper limits of normal prior to chemotherapy
- •Serum creatinine ≤ 2 times upper limits of normal or estimated glomerular filtration rate ≥ 60 mL/min/1.73 meter squared per Modification of Diet in Renal Disease equation (MDRD)
- •All subjects, except post-menopausal women, must be willing to utilize a highly effective method of contraception throughout the study
- •Adequately informed of the nature and risks of the study with written informed consent
排除标准
- •Pregnant or breast feeding
- •Overt central nervous system manifestations of leukemia at diagnosis
- •Specifically diagnosed and uncontrolled fungal, bacterial, viral, or other infection (e.g. confirmed sepsis, pneumonia, abscess, cellulitis, etc.) at the day chemotherapy is initiated. "Uncontrolled" is defined as exhibiting ongoing signs and symptoms of infection without improvement despite antimicrobial or other treatment.
- •AML subtype M3 (promyelocytic leukemia)
- •Previous chemotherapy for AML
- •History of or current human immunodeficiency virus (HIV) or hepatitis C virus infection
- •History of or current clinically significant immunodeficiency
- •Known contraindication to receiving G-CSF
- •History of or current clinically significant alloimmunization to leukocyte antigens
- •Participation in another clinical study within 28 days of the day chemotherapy is initiated, in which the study drug or device may influence hematopoiesis. Co-enrollment in another study is allowed in cases where the investigational therapy under study is a version of an acceptable chemotherapy regimen for this study per the inclusion criteria.
- •Receiving any agent concurrently with CLT-008 infusion which inhibits cell division (e.g., methotrexate or hydroxyurea)
- •Acute or chronic medical disorder that, in the opinion of the investigator or medical monitor, may prevent the subject from completing participation in the study
研究组 & 干预措施
CLT-008 high dose with G-CSF
Dose escalation
干预措施: G-CSF (Biological)
CLT-008 low dose with G-CSF
Dose escalation
干预措施: G-CSF (Biological)
CLT-008 with G-CSF
Randomized
干预措施: G-CSF (Biological)
G-CSF
Randomized
干预措施: G-CSF (Biological)
CLT-008 high dose with G-CSF
Dose escalation
干预措施: CLT-008 (Biological)
CLT-008 low dose with G-CSF
Dose escalation
干预措施: CLT-008 (Biological)
CLT-008 with G-CSF
Randomized
干预措施: CLT-008 (Biological)
结局指标
主要结局
Duration of febrile episodes (fever)
时间窗: 42 days
次要结局
- Incidence and duration of febrile neutropenia(42 days)
- Time to absolute neutrophil count (ANC) recovery(42 days)
- Incidence of Adverse Events (AE)(42 days)
- Incidence and duration of infection(42 days)
- Incidence and severity of mucositis(42 days)
- Incidence of infusion reactions(42 days)
- Incidence of Serious Adverse Events (SAE)(42 days)
- Incidence of Graft-versus-Host Disease (GVHD)(42 days)